M Holdings Securities Inc. Invests $2.14 Million in Pfizer Inc. (NYSE:PFE)

M Holdings Securities Inc. bought a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 80,816 shares of the biopharmaceutical company’s stock, valued at approximately $2,144,000.

A number of other institutional investors and hedge funds have also made changes to their positions in PFE. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer in the fourth quarter valued at $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the 4th quarter valued at about $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $31,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer during the fourth quarter worth about $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Pfizer Stock Up 0.9 %

PFE stock opened at $22.10 on Tuesday. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The stock has a market capitalization of $125.34 billion, a P/E ratio of 15.67, a PEG ratio of 0.64 and a beta of 0.67. The company has a 50 day moving average price of $25.16 and a two-hundred day moving average price of $26.33. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period last year, the company earned $0.10 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on PFE shares. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $31.07.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.